Loading viewer...
investor_presentation
Format: PDF investor_presentation
Aeterna Zentaris presents its 2017 investment opportunity focused on two FDA submissions: Macrilen for Adult Growth Hormone Deficiency and Zoptrex for endometrial cancer. The presentation highlights commercial-stage products including Apifiny and Saizen, along with a growing portfolio strategy leveraging targeted cytotoxic therapy technology.
AEL Institutional Investors Conference 2017
conferenceconference
31 Pages
investor_presentation
23 Pages
Allgeier
investor_presentation
Nomura Holdings